News Release Details

A.P. Pharma Announces First Quarter 2010 Financial Results

05/17/2010 |

REDWOOD CITY, Calif., May 17, 2010 (BUSINESS WIRE) --A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2010.

"Our focus is on addressing the issues raised in the Complete Response Letter we received for APF530 in March 2010," stated Ronald Prentki, A.P. Pharma's president and chief executive officer. "We are working with the U.S. Food and Drug Administration to schedule an End of Review meeting and have been diligently preparing our reply to the Complete Response Letter."

Operational Highlights

  • In March, the Company received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for APF530 in the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting (CINV). The Company has been working to address issues raised in the Complete Response Letter and is working with the FDA to schedule an End of Review meeting.
  • In January, an affiliate of Paul Capital Healthcare made final milestone payments totaling $2.5 million per an October 2005 agreement under which the Company sold its royalty rights to Retin-A Micro(R) and Carac(R).
  • In February, Stephen R. Davis was appointed to the Company's Board of Directors.

Results of Operations

A.P. Pharma's net loss for the first quarter of 2010 was $495,000, or $0.01 per share, compared with a net loss of $3.0 million, or $0.10 per share, for the first quarter of 2009. The improved operating results were principally due to royalty milestone payments totaling $2.5 million received in the first quarter of 2010, contract revenue from an on-going collaboration with Merial and continuing cost containment actions undertaken by the Company.

Contract revenue was $241,000 in the first quarter of 2010 compared with $8,000 for the first quarter of 2009. The increase in revenue in 2010 was primarily related to research and development work performed under an agreement with Merial entered into in September 2009 for a long-acting pain management product for companion animals.

Cash and cash equivalents as of March 31, 2010 were $7.6 million, compared with $7.6 million at December 31, 2009. As disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2009 filed with the SEC on March 15, 2010, A.P. Pharma believed it had sufficient cash resources to fund operations through 2010. On March 19, 2010 A.P. Pharma announced the receipt of a Complete Response Letter from the FDA on the APF530 NDA. In the letter, the FDA raised questions which preclude the approval of the APF530 NDA in its current form. Responding to these issues will likely change the Company's anticipated use of cash for the remainder of 2010. The full extent of activities, costs and time required to address the FDA's questions is not currently known; however, A.P. Pharma expects to clarify the actions required for resubmission and approval of its NDA at the End of Review meeting. If A.P. Pharma elects to immediately undertake all the activities that may be required to address the Complete Response Letter without further direction from the FDA, the Company would need additional capital to operate beyond the third quarter 2010. Based on multiple factors, including market conditions, the Company may not be able to obtain adequate financing to support its operations.

About APF530

A.P. Pharma's lead product, APF530, prevents both acute and delayed onset of CINV. APF530 contains the 5-HT3 antagonist, granisetron, formulated in the Company's proprietary Biochronomer(TM) drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. Intravenous and oral formulations containing granisetron are approved for the prevention of acute onset CINV, but not for delayed onset CINV. Granisetron was selected because it is widely prescribed by physicians based on a well-established record of safety and efficacy.

About A.P. Pharma

A.P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer(TM) polymer-based drug delivery technology. The Company's primary focus is on its lead product, APF530, for the prevention of chemotherapy-induced nausea and vomiting (CINV). A.P. Pharma received a Complete Response Letter on the APF530 NDA in March 2010 and is in the process of preparing a resubmission responsive to the deficiencies listed in the Complete Response Letter. The Company has additional clinical and preclinical stage programs in the area of pain management, all of which utilize its bioerodible injectable and implantable delivery systems. Further work on these programs has been deferred while the Company focuses on obtaining regulatory approval for APF530. For further information, visit the Company's web site at

A.P. Pharma, Inc.

Condensed Statements of Operations

(in thousands, except per share amounts)


Three Months Ended March 31,
2010 2009
Contract revenue $ 241 $ 8
Operating expenses:
Research and development 2,331 2,050
General and administrative 781 927
Total operating expenses 3,112 2,977
Operating loss (2,871 ) (2,969 )
Gain on sale of royalty interest 2,500 -
Interest income, net - 9
Loss from continuing operations (371 ) (2,960 )
Loss from discontinued operations (124 ) -
Net loss $ (495 ) $ (2,960 )
Basic and diluted net loss per share:
Loss from continuing operations $ (0.01 ) $ (0.10 )
Net loss $ (0.01 ) $ (0.10 )
Weighted-average common shares
outstanding--basic and diluted 39,420 30,868

A.P. Pharma, Inc.

Condensed Balance Sheets

(in thousands)


March 31, 2010 December 31, 2009
Current assets:
Cash and cash equivalents $ 7,562 $ 7,593
Accounts receivable 224 171
Prepaid expenses and other current assets 436 549
Total current assets 8,222 8,313
Property and equipment, net 455 510
Other long-term assets 128 128
Total assets $ 8,805 $ 8,951
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $ 241 $ 162
Accrued expenses 949 1,080
Deferred revenue 115 92
Accrued disposition costs 677 553
Total current liabilities 1,982 1,887
Deferred revenue 228 268
Total liabilities 2,210 2,155
Stockholders' equity:
Common stock 395 394
Additional paid-in capital 147,774 147,481
Accumulated deficit (141,574 ) (141,079 )
Total stockholders' equity 6,595 6,796
Total liabilities and stockholders' equity $ 8,805 $ 8,951

Forward-looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including uncertainties associated with capital resources and liquidity, timely development and regulatory approval of product candidates, satisfactory completion of clinical studies, establishment of new corporate alliances, progress in research and development programs, launch and acceptance of new products and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. We caution investors that forward-looking statements reflect our analysis only on their stated date. We do not intend to update them except as required by law.

SOURCE: A.P. Pharma

Corporate Contact:
A.P. Pharma, Inc.
John B. Whelan, Vice President, Finance and Chief Financial Officer
Investor and Media Relations:
Corporate Communications Alliance, LLC
Edie DeVine

Sign-Up for Email Updates

Receive news and updates on Heron’s latest innovations.